A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Human Allogeneic Cardiosphere-Derived Cells for The Treatment of Duchenne Muscular Dystrophy
Capricor Hope-3 study
What is the goal of the study?
The purpose of the clinical trial is to assess the efficacy and safety of the investigational product (IP), CAP-1002, administered every 3 months by IV infusion in subjects with Duchenne muscular dystrophy and impaired skeletal muscle function.
Who can participate in the study?
Please contact the study team listed below to learn more.